Tolterodine Tartrate (Detrol)

06/01/2006 - "We evaluated the efficacy of tolterodine extended release (ER) for patients' most bothersome overactive bladder (OAB) symptom in a primary care setting. "
04/01/2001 - "There was an improvement in voiding diary variables in all treatment groups after 2 weeks of treatment, although the efficacy was greatest in those taking 1 mg and 2 mg. Pharmacokinetic findings were consistent with dose linearity over the range 0.5-2 mg. The results support the use of 1 mg twice daily as the optimal dose of tolterodine for treating children aged 5-10 years with an overactive bladder."
11/01/2020 - "Commentary RE: Tolterodine Once Daily: Superior Efficacy and Tolerability in the Treatment of the Overactive Bladder."
05/01/2005 - "Favorable safety, tolerability and efficacy of once-daily tolterodine ER was maintained over 12 months in a Japanese overactive bladder patient population."
02/01/2003 - "A new once-daily formulation of tolterodine provides superior efficacy and is well tolerated in women with overactive bladder."

01/01/2006 - "In addition, TDOXY was similar to tolterodine, and it produced a significant improvement in the number of urinary incontinence episodes, complete continence, and urodynamic and quality of life parameters compared with placebo. "
01/01/2012 - "Parameter estimates included utilities of improved urinary incontinence (0.92) and continued urinary incontinence (0.73), reduction in quality of life from side effects (5%), cost of percutaneous tibial nerve stimulation per session ($203) and cost of tolterodine ER per month ($150). "
10/01/2013 - "A total of six randomized clinical trials and 11 other studies of tolterodine in children with urinary incontinence were included in the present systematic review. "
02/18/2009 - "Previous studies demonstrate that tolterodine extended release (ER) significantly improves urgency urinary incontinence (UUI) episodes. "
04/01/2007 - "A post hoc analysis was conducted using 3-day bladder diary data from a 12-week, multicenter, prospective, open-label study of tolterodine ER (4 mg qd) in patients (aged > or = 18 years) with urinary frequency (> or = 8 micturitions/24 h) and urgency (strong and sudden desire to urinate) with or without urgency urinary incontinence (UUI). "

04/01/2002 - "After 1 week, tolterodine ER 4 mg had produced a significant improvement in all efficacy variables in both groups of patients (P < 0.01); 72% of the maximum effect on urge incontinence was observed in both groups; and 84.7% of drug-naive patients and 83.6% of previously treated patients perceived a benefit from treatment. "
09/01/2003 - "Tolterodine is equally effective in patients with mixed incontinence and those with urge incontinence alone."
10/01/2001 - "A single trial found tolterodine extended-release 4 mg/day to have improved efficacy for decreasing urge incontinence episodes along with lower frequency of dry mouth vs. immediate-release tolterodine 2 mg bid. "
08/01/2004 - "The efficacy of tolterodine ER in reducing urge incontinence episodes was unaffected by the presence of stress incontinence. "
03/01/2001 - "Tolterodine ER demonstrated an improved efficacy for reducing urge incontinence episodes and a lower frequency of dry mouth compared with the existing IR twice-daily formulation."

09/01/2012 - "Re: The efficacy of additive tolterodine extended release for 1-year in older men with storage symptoms and clinical benign prostatic hyperplasia."
01/01/2012 - "Re: The efficacy of additive tolterodine extended release for 1-year in older men with storage symptoms and clinical benign prostatic hyperplasia."
04/01/2014 - "Seventy patients over 55 years of age who underwent transurethral resection of the prostate owing to benign prostatic hyperplasia were randomly assigned to receive either 2 mg of tolterodine twice daily (treatment group) or matched placebo during a 1-month study period. "
04/01/2011 - "To evaluate the efficacy and safety of Tolterodine Tartrate combined with the alpha-receptor blocker in the treatment of benign prostatic hyperplasia with detrusor overactivity (BPH-DO). "
04/01/2011 - "[Tolterodine tartrate combined with alpha-receptor blocker for benign prostatic hyperplasia with detrusor overactivity]."

10/27/2014 - "Tolterodine ER resulted effective in reducing frequency urgency and nocturia and urinary leakage in male patients with OAB/storage LUTS. "
01/01/2018 - "Conversely, tolterodine 4 mg did not prove to be more effective than a placebo in the reduction of nocturia episodes. "
11/01/2017 - "Night-time dosing of tolterodine ER may benefit female patients suffering from nocturia due to a greater voided volume per micturition at midnight."
11/01/2017 - "We aimed to clarify the impact of night-time dosing with tolterodine extended release (ER) on nocturia. "
10/01/2007 - "Although women taking tolterodine ER 4 mg had a consistently greater increase in mean voided volume/void and consistent decreases in incontinence episodes/24 h, urgency episodes/24 h and episodes of nocturia/24 h, this was not statistically significant. "